563 related articles for article (PubMed ID: 23382048)
1. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Takeuchi S; Yano S
Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
[TBL] [Abstract][Full Text] [Related]
3. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
4. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
5. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
6. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
[TBL] [Abstract][Full Text] [Related]
7. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
Takeuchi S; Yoshimura K; Fujiwara T; Ando M; Shimizu S; Nagase K; Hasegawa Y; Takahashi T; Katakami N; Inoue A; Yano S
J Med Invest; 2017; 64(3.4):321-325. PubMed ID: 28955007
[TBL] [Abstract][Full Text] [Related]
9. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase 3 Inhibition Overcomes
Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
[No Abstract] [Full Text] [Related]
11. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
13. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract][Full Text] [Related]
14. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
Wu DW; Chen CY; Chu CL; Lee H
Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848
[TBL] [Abstract][Full Text] [Related]
15. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
16. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
18. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
[TBL] [Abstract][Full Text] [Related]
20. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
